Search

Your search keyword '"Baccarani, MicheLe"' showing total 1,364 results

Search Constraints

Start Over You searched for: Author "Baccarani, MicheLe" Remove constraint Author: "Baccarani, MicheLe" Language english Remove constraint Language: english
1,364 results on '"Baccarani, MicheLe"'

Search Results

2. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia

5. BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS

6. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP

7. High-risk additional chromosomal abnormalities at low blast counts herald death by CML

8. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

9. Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies

10. In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent

11. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

15. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

16. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

19. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

24. Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML

28. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24

31. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

32. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

36. A population‐based study of chronic myeloid leukemia patients treated with imatinib in first line

38. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

41. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

42. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

45. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

46. Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice

Catalog

Books, media, physical & digital resources